Setting Meaningful Acceptance Criteria for Biosimilar Analytical Similarity Setting Meaningful Acceptance Criteria for Biosimilar Analytical Similarity Biosimilar development poses unique challenges within the pharmaceutical regulatory landscape, particularly regarding the establishment of meaningful acceptance criteria for analytical similarity. This regulatory explainer manual aims to provide comprehensive insights into biosimilar analytical similarity fingerprint critical quality attributes (CQAs). It addresses the landscape in the United States, the European Union, and the United Kingdom, detailing the necessary guidelines, regulatory expectations, and practical tips for Kharma and regulatory professionals involved in this intricate process. Regulatory Context The development of biosimilars is intricately governed by a…

Data visualisation tips for presenting biosimilar fingerprint data to regulators Data visualisation tips for presenting biosimilar fingerprint data to regulators The development of biosimilars has gained significant momentum due to the increasing demand for affordable biologics. A critical aspect in the approval process of biosimilars revolves around demonstrating analytical similarity and reliably characterizing their critical quality attributes (CQAs). As regulatory professionals, understanding how to effectively present fingerprint-like characterization data is key in meeting the expectations set by authorities like the FDA, EMA, and MHRA. This guide aims to provide comprehensive insights into the regulatory landscape, practical tips for data visualization,…

Governance for CQA Selection and Control Strategy in Biosimilar Programs Governance for CQA Selection and Control Strategy in Biosimilar Programs As the global landscape of biosimilars continues to evolve, selecting Critical Quality Attributes (CQAs) and establishing a robust control strategy are essential aspects for regulatory compliance in biosimilar development. This article provides a comprehensive guide on the governance surrounding biosimilar analytical similarity fingerprint CQAs, and offers insights on how to navigate the regulatory expectations as established by key authorities such as the FDA, EMA, and MHRA. Regulatory Context Biosimilars are biological products highly similar to an already approved reference product,…

Global comparability and bridging analytical data across multiple sites Global Comparability and Bridging Analytical Data Across Multiple Sites Biosimilars have transformed the landscape of biologics, enabling increased patient access to effective therapies while stimulating competition in the pharmaceutical market. One critical aspect of biosimilar development is ensuring analytical similarity, particularly regarding the assessment of critical quality attributes (CQAs). This article serves as a regulatory explainer manual detailing the regulatory context, guidelines, documentation requirements, and review processes involved in demonstrating analytical similarity using fingerprint-like characterization and bridging analytical data across multiple sites. Regulatory Context for Analytical Similarity Analytical similarity is a…

Comparing US and EU expectations for analytical similarity packages Comparing US and EU Expectations for Analytical Similarity Packages Introduction to Biosimilar Development and Regulatory Framework Biosimilar development represents a significant and complex area within the biopharmaceutical landscape, requiring a comprehensive understanding of various regulatory frameworks. In both the United States and the European Union, the assessment of analytical similarity between a biosimilar and its reference product is crucial for gaining regulatory approval. This document delves into the expectations set forth by the FDA and the EMA regarding analytical similarity packages, particularly focusing on fingerprint-like characterization and critical quality attributes (CQAs)….